Editorial Contributions & Industry Insights

As an international key opinion leader with extensive experience in the healthcare ecosystem, I have been at the forefront of shaping industry discussions and policy. Since 2018, I have contributed to PharmaBoardroom, offering in-depth analysis and insights on emerging trends, regulatory changes, and strategic developments within the global healthcare landscape. My work is grounded in a deep understanding of the industry's complexities, making me a trusted voice for stakeholders across the healthcare spectrum.

Read More Here

Featured Posts

Blog
CON Laws and the ACA — The Next Frontier for Affordable Healthcare Reform
CON Laws and the ACA — The Next Frontier for Affordable Healthcare Reform

More than a decade after the Affordable Care Act expanded coverage for millions, a harsh reality remains: coverage does not equal access. Premiums continue to rise, rural care deserts are widening, and consolidated insurers and middlemen dominate every layer of the system. In this article, I explore the ACA’s most overlooked weakness—its failure to confront the structural barriers that suppress competition. From Certificate-of-Need laws to PBM pricing distortions and marketplace consolidation, these forces inflate costs and restrict care long before patients reach the exam room. To achieve true affordability and access, we must finish the job the ACA started by opening the system to innovation, transparency, and competition.

A Manufacturing-Commons for America’s Medicines
nationaldefense, manufacturing, raredisease, syngap1, healthpolicy, tariffs, genericdrugs
A Manufacturing-Commons for America’s Medicines
nationaldefense, manufacturing, raredisease, syngap1, healthpolicy, tariffs, genericdrugs

COVID-19 exposed a fragile pharmaceutical supply chain — hollowed out by decades of offshoring and rising costs. Today, the U.S. faces a choice: rebuild domestic drug manufacturing or remain dependent on foreign factories. A bold, practical solution is emerging — National Centers of Excellence for Pharmaceutical Manufacturing — shared regional hubs that provide GMP-certified facilities, workforce training, and surge capacity to ensure secure, affordable medicines made on American soil. Supported by President Trump’s recent Executive Order to restore domestic production, these centers could revive our industrial base, protect national security, and make drugs more accessible. The next crisis won’t wait — and neither should we.

nationaldefense, manufacturing, raredisease, syngap1, healthpolicy, tariffs, genericdrugs
A Call for Collective Responsibility in Rare Disease Communities
A Call for Collective Responsibility in Rare Disease Communities

Drawing on her experience as rare disease patient advocacy group SYNGAP1 Foundation’s founder and former president, Monica Weldon argues for the need to standardize genomic testing practices, warns against the possible ethical implications of individualized medicine, and makes a cause for a more holistic approach within rare disease communities.

Efficacy or Economics? The US Promising Pathways Act 2.0 and the Future of Innovation
Efficacy or Economics? The US Promising Pathways Act 2.0 and the Future of Innovation

The Promising Pathways Act 2.0 is a newly proposed bill that aims to expedite and streamline approval pathways for rare disease therapies in the US. The Act is, however, facing a number of challenges in terms of implementation. The sponsors of these niche therapies tend to be small and medium-sized biotech firms which are unable to compete with the financial might of Big Pharma and also struggle to deal with the myriad regulatory hurdles they need to jump over. Monica Weldon, a frequent PharmaBoardroom contributor and rare disease patient advocate, who helped craft the bill, explains more.

Read More
ACA, Healthcare Policy, Insurance Monica Dudley-Weldon ACA, Healthcare Policy, Insurance Monica Dudley-Weldon

CON Laws and the ACA — The Next Frontier for Affordable Healthcare Reform

More than a decade after the Affordable Care Act expanded coverage for millions, a harsh reality remains: coverage does not equal access. Premiums continue to rise, rural care deserts are widening, and consolidated insurers and middlemen dominate every layer of the system. In this article, I explore the ACA’s most overlooked weakness—its failure to confront the structural barriers that suppress competition. From Certificate-of-Need laws to PBM pricing distortions and marketplace consolidation, these forces inflate costs and restrict care long before patients reach the exam room. To achieve true affordability and access, we must finish the job the ACA started by opening the system to innovation, transparency, and competition.

Read More

Subscribe to our newsletter.

Sign up with your email address to receive news and updates.